Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prolonged midazolam elimination half-life.

J W Dundee, P S Collier, R J Carlisle

    British Journal of Clinical Pharmacology
    |April 1, 1986
    PubMed
    Summary

    A standard midazolam dose revealed a prolonged elimination half-life in 6% of healthy subjects. This suggests impaired hepatic metabolism may cause this pharmacokinetic abnormality in some individuals.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Intravenous anesthesia--Chairman's opening and closing remarks. 1962.

    International anesthesiology clinics·1999
    Same author

    Antiemetic or antinauseant effect of ondansetron?

    Anesthesia and analgesia·1992
    Same author

    Is ondansetron a less effective antiemetic against moderately emetic as compared with highly emetic chemotherapy?

    British journal of clinical pharmacology·1992
    Same author

    P6 acupressure and postoperative vomiting.

    British journal of anaesthesia·1992
    Same author

    Advantages and problems with benzodiazepine sedation.

    Anesthesia progress·1992
    Same author

    Safety of alcohol after midazolam.

    Anesthesia and analgesia·1991

    Area of Science:

    • Pharmacology
    • Clinical Pharmacy
    • Drug Metabolism

    Background:

    • Midazolam is a commonly used sedative.
    • Understanding its pharmacokinetics is crucial for safe and effective dosing.
    • Individual variability in drug response necessitates pharmacokinetic studies.

    Purpose of the Study:

    • To investigate the pharmacokinetics of a fixed intravenous dose of midazolam (0.3 mg kg-1).
    • To identify and characterize individuals exhibiting prolonged elimination half-life.
    • To explore potential factors contributing to altered midazolam metabolism.

    Main Methods:

    • Pharmacokinetic analysis of midazolam in healthy subjects.
    • Intravenous administration of a fixed midazolam dose (0.3 mg kg-1).
    • Detailed and abbreviated pharmacokinetic studies were conducted.

    Main Results:

    • A prolonged elimination half-life was observed in 9 out of 115 subjects during detailed studies.
    • Five out of 102 subjects in abbreviated studies also showed similar abnormalities.
    • Approximately 6% of over 200 healthy subjects exhibited this pharmacokinetic phenomenon.

    Conclusions:

    • A significant proportion of healthy individuals may exhibit altered midazolam pharmacokinetics.
    • Defective hepatic metabolism is a potential contributing factor to prolonged midazolam elimination.
    • This highlights the importance of considering individual metabolic capacity in midazolam therapy.

    Related Experiment Videos